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Abstract
Two genetically engineered, conditional mouse models of lung tumor formation, K-rasLSL-G12D and K-rasLSL-G12D/
p53LSL-R270H, are commonly used to model human lung cancer. Developed by Tyler Jacks and colleagues, these
models have been invaluable to study in vivo lung cancer initiation and progression in a genetically and physiologi-
cally relevant context. However, heterogeneity, multiplicity and complexity of tumor formation in these models
make it challenging to monitor tumor growth in vivo and have limited the application of these models in oncology
drug discovery. Here, we describe a novel analytical method to quantitatively measure total lung tumor burden in
live animals using micro–computed tomography imaging. Applying this methodology, we studied the kinetics of
tumor development and response to targeted therapy in vivo in K-ras and K-ras/p53mice. Consistent with previous
reports, lung tumors in both models developed in a time- and dose (Cre recombinase)–dependent manner. Fur-
thermore, the compound K-rasLSL-G12D/p53LSL-R270H mice developed tumors faster and more robustly than mice
harboring a single K-rasLSL-G12D oncogene, as expected. Erlotinib, a small molecule inhibitor of the epidermal
growth factor receptor, significantly inhibited tumor growth in K-rasLSL-G12D/p53LSL-R270H mice. These results dem-
onstrate that this novel imaging technique can be used to monitor both tumor progression and response to treat-
ment and therefore supports a broader application of these genetically engineered mouse models in oncology
drug discovery and development.
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Introduction
Lung cancer is the leading cause of cancer deaths worldwide [1].
Mutations in K-ras proto-oncogene are closely associated with approx-
imately 30% of non–small cell lung cancers. Expression of an onco-
genic mutant K-rasG12D gene in lung tissues of mice resulted in the
development of lung adenocarcinoma, resembling human lung can-
cers [2,3]. Alterations in the p53 tumor suppressor gene are also found
in 50% human non–small cell lung cancer patients [4]. Conditional
expression of a p53R270H dominant-negative mutant gene using the
Cre-lox recombinase system promotes K-rasG12D–initiated lung
adenocarcinomas in a compound knock-in mouse model [5,6]. This
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conditional compound knock-in mouse line contains a Lox-Stop-Lox
(LSL) K-rasG12D (referred to as K-rasLSL-G12D, or K-ras) and a Lox-
Stop-Lox p53R270H (referred to as p53LSL-R270H, or p53) transgenes.
The oncogenic K-rasG12D and the dominant-negative tumor suppres-
sor gene p53R270H are simultaneously expressed by the removal of
transcriptional termination Stop element in the LSL cassette when
the Cre recombinase is expressed [7,8]. Intranasal introduction of
the Cre recombinase by Adeno-Cre viral infection activates expres-
sion of these two genes in lung tissue, leading to the development of
lung adenocarcinoma.
Application of lung cancer animal models for drug discovery has
been challenging. Tumor progression and phenotype is determined
by grading tumor stages with histologic examination [6]. Tumor bur-
den is currently measured by examining the percentage of total lung
area occupied by tumor in a histologic slice. These time-consuming
assessments lack accuracy because of the limited areas of lung tissue
analyzed. Computed tomography (CT) imaging has been used for
the detection of lung cancer in human clinical settings and in preclin-
ical studies using laboratory animals. However, lung tumor measure-
ment has been limited in mouse models to quantify discrete tumors
that are large and located away from major vascular structures [9,10].
Micro-CT has also been applied in the K-ras knock-in model by
counting the number of tumors and measuring three to five individ-
ual tumors in each animal [11,12]. However, small tumors are hard
to distinguish from vasculature and difficult to measure. It is particu-
larly challenging to quantify individual tumor volumes in these lung
models because intranasal adenoviral infection leads to formation of
multifocal small tumors with irregular shapes. Although attempts
have been made to monitor protease activity during tumor initiation
and progression in this model using the fluorescence molecular to-
mography imaging technique [13], it has not been applied to quan-
tify tumor burden in drug discovery. To enhance incorporation of
these lung tumor genetic mouse models into drug discovery programs,
we developed a high-throughput analytical method using micro-CT
images to quantitatively measure total lung tumor burden. This novel
analytical method was evaluated using the well-characterized tumor
progression in K-ras and K-ras/p53models [6,14]. K-ras–drivenmouse
lung tumors have been reported to be sensitive to epidermal growth
factor receptor tyrosine kinase inhibitors [15,16], which have not
been shown to be effective in human lung tumors [17,18]. However,
to test our methodology in a therapy setting, tumor-bearing K-ras/p53
mice were treated with erlotinib.
Materials and Methods
Animals
All animal procedures were reviewed and approved by the Merck-
Boston Institutional Animal Care and Use Committee. K-rasLSL-G12D/
p53LSL-R270H (K-ras/p53 or KP) and K-rasLSL-G12D (K-ras or K) mouse
models were licensed form Dr. Tyler Jacks’ laboratory at MIT,
Cambridge, MA, and mouse colonies were maintained at Taconic,
Germantown, NY. Mixed sexes of mice approximately 2 months old
were received from Taconic. At Taconic, mice were housed in groups
in a barrier rodent facility using the isolated barrier unit system on
wood chip bedding and fed standard rodent chow ad libitum. Mice
were tested for routine mouse pathogens and were found to be nega-
tive. Mice were acclimated for 1 week inMerck Research Laboratories,
Boston animal facility, before initiating imaging studies.
Animal Treatments
For the tumor development study, mice were intranasally infected
with either a low dose (1 × 107 plaque-forming units (PFUs)), me-
dium dose (2.5 × 107 PFU), or high dose (5 × 107 PFU) of adenovirus
containing Cre recombinase (Adeno-Cre) purchased from Vector
BioLabs, Philadelphia, PA. Control adenovirus containing an empty
vector was administered at the high dose (5 × 107 PFU). Mice were
then scanned using micro-CT at weeks 8, 14, 18, and 20 after infec-
tion. Group sizes varied from 2 to 6 animals for control viral–infected
groups and from 6 to 17 animals for Cre viral–infected groups at
different time points. At week 8, groups include control KP (n = 2),
high-dose KP (n = 4), control K (n = 2), and high-dose K (n = 3). At
week 14, groups include control KP (n = 5), high-dose KP (n = 16),
medium-dose KP (n = 17), control K (n = 6), high-dose K (n = 7), and
medium-dose KP (n = 14). At weeks 18 and 20, groups include control
KP (n = 3), high-dose KP (n = 8), medium-dose KP (n = 9), control K
(n = 4), high-dose K (n = 8), and medium-dose KP (n = 7). To validate
imaging method for therapy studies, erlotinib therapy was evaluated
in K-ras/p53 knock-in mice (n = 12-15) 16 weeks after Adeno-Cre vi-
ral infection, and animals were orally treated once daily for 4 weeks
with erlotinib at 75 or 150 mg/kg or with vehicle. Erlotinib was dis-
solved in vehicle containing 1% methylcellulose and 0.1% Tween-80
and was orally administered once daily. Micro-CTwas performed be-
fore and after drug treatments.
Micro-CT Imaging
Mice were anesthetized with a continuous flow of 2% to 4%
isoflurane/oxygen mixture (2.5 L/min), and the whole body was able
to be imaged at one time using the GE eXplore Locus Ultra Pre-
Clinical CT scanner (GE Healthcare, London, Canada). The isotropic
resolution of this instrument is 185 μm. The micro-CT image acqui-
sition consisted of 1000 projections collected in one full rotation of the
gantry in approximately 16 seconds. The image acquisition was not
respiratory-gated. The X-ray tube settings were 80 kV and 70 mA.
The resulting raw data were reconstructed to a final image volume
of 512 × 512 × 1000 slices at 100-μm3 voxel dimensions. The re-
constructed slices were output in the CT manufacturer’s raw format
and were not scaled to Hounsfield units. The reconstructed images
were viewed and analyzed using the Amira 4.1.1 software (Mercury
Computer Systems, Inc., Chelmsford, MA).
Volumetric Measurement of Tumor Volume
The image analysis method was based on using threshold and
region-grow algorithms to segment the image data and define the
separate anatomic structures of interest. As a first step, images were
cropped to display the lung region. Then, the functional lung vol-
ume was determined by using a threshold-based region grow algo-
rithm with voxel value thresholds set from 450 to 800 to segment
air space in the lung. Next, the total chest space volume, excluding
the heart, was selected using a combination of manual segmentation
and semiautomated contouring. Vascular structures around the heart
were manually included in the total chest space. The combined tu-
mor and vasculature (T & V) volume was then determined by sub-
tracting the functional lung volume from the total chest space
volume. Because tumor tissue and vascular tissue have similar gray-
scale values, they cannot be separated using this analysis method.
However, nontumor vasculature volume should remain relatively
constant as tumor volume increases over time. Thus, this method
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can provide a relative measure of tumor burden. All data are pre-
sented as mean ± SE.
Histology Examination of Lung Tissues
For histologic diagnosis, formalin-fixed, paraffin-embedded blocks
of the left side of the lung were cut in a transverse manner. Serial
slices, 5 to 8 μm thick, of lung tissue were prepared by hematoxylin
and eosin (H&E) staining. Slides were scanned with an Ariol SL-50
automated microscope and image analyses software (Applied Imag-
ing, San Jose, CA) at 5× magnification. Total lung and tumor areas
were manually demarcated by Ariol Review software, and data were
presented as percent of tumor area.
Statistical Analysis
A repeated-measures analysis of variance (ANOVA) was used to
assess statistically significant differences. Post hoc one-sided tests were
performed with Bonferroni adjustment. For the tumor development
experiment (Figures 2A and 4A), 24 statistical contrasts were esti-
mated: for each time point, these were the differences in total T & V
volume between each dose (high or low) for each animal model versus
the corresponding control for that time point and animal model, as
well as the within-group differences of each time point with the ear-
liest available time point (8 weeks for high dose, 14 weeks for low
dose). Similar analyses were done for the lung and chest volumes
but with only the within-group contrasts calculated (Figure 4A).
For the erlotinib therapeutic study (Figure 5), five statistical contrasts
were estimated. These include three tests for change from baseline of
total T & V volume within each group. These also include two tests
for the difference between both doses versus vehicle at the postdosing
time point, subtracting the appropriate predose difference. These sta-
tistical results were consistent with those from a one-way ANOVA on
the percent change from baseline scores (with Bonferroni adjust-
ment; Figure 5B). The repeated-measures ANOVA analysis is equiv-
alent to that when the end point is made to be total T & V volume
minus the overall baseline vasculature volume of 128 mm3. Separate
t tests were done comparing the groups at baseline, simply to illus-
trate the heterogeneity of the sample before treatment.
Results
Quantitative Measurement of Total Lung Tumor Burden in
K-ras/p53 and K-ras Model
We developed a micro-CT image analysis method to quantitatively
measure the sum of T & V volume as a readout of total tumor bur-
den in lung. Noncontrast micro-CT imaging cannot readily distin-
guish tumor tissue from vasculature because the two tissues have
similar X-ray densities. However, one would expect that total tumor
burden would be proportional to the combined T & V volume in the
lung. Voxel grayscale values between 450 and 800 were considered as
functional lung volume, whereas grayscale values above 800 within
the chest space except for heart were calculated as T & V. The T & V
volume was then calculated by subtracting the functional lung vol-
ume from the total chest space (Figure 1).
Using this method, we studied the time course of tumor develop-
ment in both the single K-ras and compound K-ras/p53 knock-
in mouse models. Mice from each model were infected with either
Figure 1.Method of micro-CT measurement of total tumor burden in lung GEMMs. Tumor and vasculature were measured to represent
total tumor burden. The image was adjusted to 450 to 800 grayscale to define boundaries between functional lung area, vasculature,
tumor, and chest. (A) Total chest space volume in red includes vessels that come from the heart. (B) Lung area in red with lower CT
density was then quantified. Tumor and vasculature were calculated by subtracting the functional lung volume from the total chest
space. (C) The total image histogram is shown with the region grow threshold set between 450 and 800.
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Figure 2. ValidationofCT imageanalysismethod anddetectionof tumordevelopment inK-ras/p53 andK-ras transgenicmodels. K-rasLSL-G12D/
p53LSL-R270H (KP) or K-rasLSL-G12D (K) mice were infected with control adenovirus or with a high or low dose of Adeno-Cre virus. Mice
were imaged at 8, 14, 18, and 20 weeks after infection. (A) Tumor development was depicted as total T & V volume over time. The bold black
line indicates the average baseline vasculature, 128 mm3. (B) Spearman’s rank correlation between CTmeasurement and histologic assess-
ment of individual animals. (C) Trend correlation approximation using averages of group data fromB. (D and E) Time and dose dependence of
tumor development in the same animals assessed by histology and CT analysis. **P< .01, statistically significant compared to their vehicle
controls. “+” and “+++” indicate that one and three animals with highest tumor burden in their groupswere found dead before or during CT
scan, respectively.
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control adenovirus lacking the Cre gene (Adeno-Null) or high (5 ×
107 PFU) or low (1 × 107 PFU) doses of Adeno-Cre virus. Mice
were scanned using micro-CT at 8, 14, 18, and 20 weeks after viral
infection. Eight weeks after infection there was no significant in-
crease in T & V volume in either GEM model, although a trend
increase was noted in the K-ras/p53 mice treated with the high dose
of Adeno-Cre virus compared to control animals (Figure 2A). At
week 8, the total vasculature volume in lung space infected with con-
trol Adenovirus was between 72 and 122 mm3. The average of T
& V volume in KP and K mice infected with the high dose of Adeno-
Cre virus was 122 and 95 mm3, respectively, suggesting that mice did
not develop detectable tumor burden 8 weeks after infection. With
time, animals infected with the high dose of Adeno-Cre virus in both
models showed significant increases in T&V volume compared to con-
trol animals, whereas a trend of increase was noted in both models with
a low dose of infection (Figure 2A). In addition, these data suggest that
the K-ras/p53 compound knock-in mice developed tumors faster and
more robustly than the K-ras mice, which is consistent with literature
reports [6]. The average of total T &V volume in KP group with a high
dose of Adeno-Cre increases from 122 ± 12mm3 at week 8 to 240 ± 22,
518 ± 49, and 520 ± 51 mm3 at 14, 18, and 20 weeks after infection,
respectively. The average vasculature volume calculated from all themice
(n = 29) that were infected with control Adeno-null virus at all time
points was 128 ± 7 mm3. This baseline vasculature volume was used
to approximate the actual tumor volume by subtracting it from the total
T & V volume.
To determine whether the T & V volume imaging measurements
represent the actual tumor burden, we measured percentage of tumor
area from two-dimensional histologic slices and compared it with T
& V volume measured by CT imaging from the same animals. Ani-
mals from the time course experiment and a drug test experiment
were euthanized after the final micro-CT imaging session. The left
lobe of the lung was collected for histologic examination and percent-
age of tumor area calculated from the histologic sections. Because
the imaging measurement is a volume and the histologic measure-
ment is a percentage of area, there should be a monotonically increas-
ing, but nonlinear, relation between the two sets of measurements.
Spearman’s rank correlation, a nonparametric (model-free) assess-
ment of the degree of monotonic association between two variables,
was performed. Data from 38 animals from six different groups were
Figure 3. Representative micro-CT images of lung tumors from Figure 2. (A) Visualization of lung tumor development in K-rasLSL-G12D/
p53LSL-R270H (KP) or K-rasLSL-G12D (K) models. Panel 1: Example of CT images of a control KP mouse with no tumor and H&E stain. Panel 2:
Example of CT images of a KP mouse infected with a high dose of Adeno-Cre virus with isolated lung tumors and H&E stain. Panel 3:
Example of CT images of a KP mouse infected with a high dose of Adeno-Cre virus with small multifocal tumors and H&E stain. (B) Lung
images of macrophage infiltration and histologic staining with a purified rat antimouse Mac-3 antibody (BD Pharmingen, Mississauga,
Ontario, Canada) in virus-infected mice. Blue arrow indicates microphage filled lung; white arrow, normal vasculature; yellow line, iso-
lated tumor.
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pooled, and a nonparametric smooth curve (Figure 2B) was fit to the
data using a loess (robust local linear smoother) with a bandwidth of
2/3. This correlation (R2 = 0.79) is statistically significantly higher
than zero chance of correlation with P < .001. Considering that tu-
mor burden measured from one slice of the left side of the lung by
histologic diagnosis may not represent the total tumor burden, we
compared the means from different groups. Total tumor burden
measured by histologic diagnosis (Figure 2D) was increased in a time-
and Cre dose–dependent manner, which is consistent with total T &
V volume measurement by micro-CT (Figure 2E ). The averages of
tumor burden from all six groups of mice measured by histologic di-
agnosis and micro-CT showed an excellent correlation with R2 =
0.98 using a polynomial approximation (Figure 2C ).
Micro-CT Imaging Reveals Complexity of the Lung
Tumor Models
Micro-CT not only detected isolated large tumors that had distinct
boundaries (Figure 3A, panel 2) but also revealed the multiplicity of
tumor development spread throughout the entire lung (Figure 3A,
panel 3). It was difficult to distinguish these small tumors from vascu-
lar structures and to quantify volumes of individual tumor nodules.
Even for larger isolated tumors, lesions often fused or connected to
each other in different areas and the irregular shapes of tumors made
it even more difficult to define tumor boundaries for volumetric mea-
surement. Histologic examination of lung slices at the end point
confirmed the presence of tumors viewed by micro-CT images
(Figure 3A). In addition, micro-CT images revealed that in some ani-
mals (2/13) 8 weeks after a high dose of viral infection, the left side
of the lung was completely opaque and filled (Figure 3B). This in-
creased cellularity in the left side of the lungs was caused by macro-
phage infiltration resulting from inflammation due to viral infection,
which is a common feature of the model [6,12]. These imaging find-
ings were confirmed by histologic examination stained with an anti–
Mac-3 monoclonal antibody that detects Mac-3 antigen on tissue
macrophages, thioglycollate-elicited peritoneal macrophages, and
some myeloid cell lines, but not on lymphocytes or monocytes
(Figure 3B). However, this phenomenon was rarely observed at later
time points. Of more than 200 animals 15 to 17 weeks after infection
with high doses of Adeno-Cre virus, only onemouse was found to have
a complete macrophage-filled lung and was excluded from enrollment
of the efficacy study.
Interestingly, we noted that the animal chest space was enlarged as
the tumor burden increased. We analyzed the time course data by
grouping the KP and K mice together and compared chest space
and T & V volume because both KP and K mice developed lung
tumors in a similar fashion. As shown in Figure 4A, increases in T
Figure 4. Enlargement of chest space associated with tumor growth. (A) Chest space and lung volume were measured. The tumor and
vasculature (T & V) volume was calculated. Data from KP mice induced by control or Adeno-Cre virus were depicted. (B) Relationship
between chest space and lung volume from 458 individual measurements. (C) Relationship between chest space and calculated T & V
volume. (D) Relationship between T & V and lung volumes. **P= .01, statistical significant compared to the values of theweek 8 time point
(for KP high) or the week 14 time point (for KP low).
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& V volume in both high- and low-dose groups was clearly associated
with increases in chest space. To further confirm this phenomenon,
several in-house experiments were pooled using 458 separate mea-
surements. The data (Figure 4, B and C ) demonstrated that increases
in T & V volume were associated with increased chest spaces with
Pearson’s correlation R2 = 0.65 with 95% confidence and that this
increased chest space volume was also associated with increased
lung volume (R2 = 0.53). The solid lines in Figure 4, B and C ,
are 45-degree lines. Because either T & Vor lung volumes are smaller
than total chest volumes, all data points must be below this upper-
bound 45-degree line.
Erlotinib Suppressed Lung Tumor Growth in the Compound
K-ras and p53 Lung Tumor Model
Previous reports demonstrated that the epidermal growth factor re-
ceptor inhibitor gefitinib suppressed tumor growth in a K-ras trans-
genic model [15] and that erlotinib had inhibitory effects on lung
adenocarcinoma with both K-ras and p53 mutations in a chemically
induced mouse tumor model [16]. To validate our imaging method-
ology, we tested the effect of erlotinib in the compound K-ras/p53
mouse model. Sixteen weeks after Adeno-Cre infection, mice were
randomized into three groups (n = 12-15) and scanned with micro-
CT before dosing to obtain baseline tumor burden. The mice were
then orally treated once daily for 4 weeks with erlotinib at 75 and
150 mg/kg or vehicle and scanned with micro-CT. The total T
& V volume significantly increased from 357 ± 28 to 451 ± 30 mm3
in vehicle-treated animals, whereas T & V volumes in erlotinib-treated
animals slightly decreased from 448 ± 31 to 382 ± 33 mm3 for the
75-mg/kg group and from 431 ± 35 to 375 ± 26 mm3 for the
150-mg/kg group (Figure 5A). Tumor burden was calculated by sub-
tracting the baseline vasculature volume of 128 mm3. We calculated
percentage changes of tumor volumes (vasculature baseline subtracted)
to normalize initial tumor burden among groups because it was noted
that the predosing tumor burden in the vehicle group was significantly
lower than the 75-mg/kg erlotinib group (Figure 5). Tumor burden was
reduced to 81% and 94% of predosing levels for the 75- and 150-mg/kg
groups, respectively, whereas tumor burden in the control group in-
creased to 169% of the predosing level (Figure 5B). This result is similar
to the previous report [15], further validating this imaging analy-
sis methodology.
Discussion
The biopharmaceutical industry has been aggressively looking for
more predictive animal models and advanced imaging techniques to
increase the probability of success of advancing preclinical drug candi-
dates to human clinical trials. For oncology, tumor xenograft models
in immunodeficient mice remain the standard model to initially test
and select compounds. However, these models poorly resemble hu-
man cancers and clinical trial results because the integrity of signaling
Figure 5. Effect of erlotinib on lung tumor growth in the compound knock-in mouse model. K-rasLSL-G12D/p53LSL-R270H (KP) mice were
infected with Adeno-Cre virus. Mice were randomly assigned into study groups 16 weeks after infection and were treated. (A) Effect on
T & V volume and calculated tumor volumes by subtracting the baseline vasculature, 128 mm3. (B) Percentage changes in calculated
tumor volume over predosing. **P < .01, statistical significant compared to vehicle controls. + P < .05, statistical significant compared
to predosing values within the same group. #P < .05, statistically significant difference (t test) between groups at the predosing
time point.
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pathways, mutation status, stromal cell interaction, etc., are altered
by cell culture, implantation processes, and tumor-host interactions
[19]. Genetically engineered mouse models (GEMMs) created by in-
troducing oncogenes or altering tumor suppressor genes in the mouse
genome can mimic human cancer development in several aspects. Ge-
netically engineered mouse models have been proposed as additional
models for preclinical assessment of drug candidates to complement
the widely used xenograft models [20]. However, application of these
GEMMs is hampered by relatively high cost, complex breeding pro-
cess, mixed genetic backgrounds, extended tumor latency, and, in par-
ticular, difficulty of internal tumor detection and measurement.
The K-ras and the K-ras/p53 compound conditional knock-in
mouse models are two GEMMs that faithfully recapitulate character-
istics of the human lung adenocarcinoma disease [6]. Micro-CT has
been used to characterize lung tumor mouse models by qualitative
assessment or quantitative measurement of individual tumors [21–
23]. Most traditional micro-CT instruments take 10 to 20 minutes
to scan the entire mouse body. This relatively low throughput limits
micro-CT application to drug discovery because of the number of
animals required in each study to reach statistical significance. For
most GEMM studies, large cohorts of animals are needed owing
to the complexity and variability of tumor latency, tumor penetrance,
and growth kinetics. Therefore, development of a higher-throughput
imaging protocol will greatly facilitate use of these models in drug
efficacy studies. The high-throughput method for the quantifica-
tion of lung tumor burden in this report used the GE eXplore Locus
Ultra Pre-Clinical CT scanner, which allowed us to acquire micro-CT
images of the whole body of two mice in only 16 seconds. This
throughput translates into the realistic ability to perform imaging
studies on more than 100 mice/day. The relatively fast acquisition
times of this micro-CT scanner is offset by its relatively lower intrin-
sic resolution compared to other micro-CT instruments. Volumetric
analysis of tumor burden is another limiting factor of throughput.
Quantification of individual tumors by manually drawing regions
of interest of individual tumors can be very time-consuming. For
the K-ras/p53 model, in particular, mice normally develop multifocal
small tumors that are visible but may not be quantifiable. The method
described in this report is semiautomated by applying a threshold-
based region grow algorithm and approximately 25 to 30 mice can
be analyzed per day. This analytical approach measured not only the
isolated tumors but also the small multifocal tumors that are not
measurable by manually drawing regions of interest. Therefore, this
method should represent more precisely the total tumor burden as
confirmed by histologic data. The relatively poor correlation between
histologic tumor areas and micro-CT tumor volumes among individ-
ual animals most likely arose from the limited histologic sampling. In-
deed, a single slice of the left side of the lung does not capture and
represent location, distribution, and irregular shapes of the tumors.
The mean of tumor areas from a group of mice more accurately reflects
tumor burden by averaging both underestimated and overestimated
values (Figure 2C). Another advantage of this micro-CT analysis ap-
proach is that tumor development and response to drug treatment
could be monitored longitudinally, whereas histologic examination is
a terminal readout. As noted in the erlotinib experiment, with groups
of 12 to 15 animals, the initial tumor burden before treatments varied
markedly among three groups, although animals were randomly as-
signed. Noninvasive micro-CT imaging allows us to follow tumor
growth more accurately by normalizing to predosing tumor burden.
It makes it possible to prescreen and select animals with a certain range
of tumor volumes as animal enrollment criteria to reduce group vari-
ability of tumor burden.
Using micro-CT, we detected increased lung opacity, which was
determined to be macrophage infiltration with the histologic finding
caused by viral infection 8 weeks after infection. Accumulation of
macrophage cells in the lung may potentially interfere with tumor
quantification. However, macrophage infiltration was mostly ob-
served primarily in the early stages of infection when there was no
significant tumor formation. This phenomenon was rarely observed
at 14 weeks or later after viral infection when tumors become detect-
able. It will be necessary to prescreen animals and exclude animals
that have acute inflammatory responses. Because micro-CT cannot
distinguish infiltrated macrophages from tumor or vasculature, this
method may falsely include local macrophage infiltration if animals
do have lung infections. However, we did not observe significant
macrophage infiltration in these two models after 14 weeks of viral
infection either by imaging or by histologic analysis.
The method described here does not distinguish vascular tissue
from tumor tissue. Non–contrast-enhanced micro-CT does not gen-
erate enough contrast between T & V volume to differentiate the tis-
sues. Vasculature volume may increase as tumors grow and recruit
additional vascular supply. However, the relative total tumor burden
should be accurately approximated by measuring the total tumor
and vessel volume. As noted, tumor burden measured by micro-CT
was consistent with histologic assessment (Figure 2). We also found
unexpectedly that tumor development was associated with the increase
in the chest space volume. It is possible that tumor growth physically
expanded the chest volume owing to size restraints. In addition,
growth of tumor tissue may impair lung function that will reduce lung
respiration. Another limitation of this method is that the micro-CT
image acquisition was not respiratory-gated. Respiratory motion can
introduce blurring of image edges [21], which would result in an over-
estimation of the total tumor burden. Variability in the respiratory
rate of individual mice may also affect tumor burden measurement.
In summary, we have developed a high-throughput quantitative
analytical method to measure total tumor burden in lung using
micro-CT. This approach makes it possible to evaluate oncology ther-
apeutic compounds in complex genetically engineered lung tumor
mouse models.
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